Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab Combined With Chemotherapy for EGFR Mutant NSCLC With Leptomeningeal Metastasis
NCT06766591Not yet recruiting
- Sponsor
- Affiliated Brain Hospital of Nanjing Medical University
- Start
- Jan 2025
- Primary completion
- Oct 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Open-label, single-arm trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Affiliated Brain Hospital of Nanjing Medical University. Primary endpoint: Intracranial Progression-Free Survival at 12 months. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06766591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06766591.